Company Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders.
The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial.
It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial.
The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses.
Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
| Country | United States |
| IPO Date | Oct 9, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Dr. Javier Szwarcberg M.D., M.P.H. |
Contact Details
Address: 2001 Junipero Serra Boulevard Daly City, California United States | |
| Website | https://www.sprucebiosciences.com |
Stock Details
| Ticker Symbol | SPRB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001683553 |
| CUSIP Number | 85209E109 |
| ISIN Number | US85209E1091 |
| Employer ID | 81-2154263 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Javier Szwarcberg M.D., M.P.H. | Chief Executive Officer & Director |
| Samir M. Gharib CPA, M.B.A. | President & Chief Financial Officer |
| Dr. Kirk Ways M.D., Ph.D. | Interim Chief Medical Officer & Director |
| Heidi Petersen M.P.H. | Senior Vice President of Regulatory & Quality |
| Michael G. Grey | Executive Chairman |
| P. J. Ramtin | Senior Vice President of Business Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Dec 27, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 4 | Filing |
| Dec 20, 2024 | 4 | Filing |
| Dec 20, 2024 | 4 | Filing |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 8-K | Current Report |